<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693821</url>
  </required_header>
  <id_info>
    <org_study_id>2575</org_study_id>
    <nct_id>NCT02693821</nct_id>
  </id_info>
  <brief_title>Persistent Postoperative Pain</brief_title>
  <acronym>PPP</acronym>
  <official_title>Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's objective will be to evaluate the gabapentine efficiency in orally and long term
      used after painfully surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be: controlled, prospective, randomized and double blind.

      Its main objective will be to evaluate the pre and postoperative Gabapentin efficiency in
      orally doses and long term used of it in order to prevent or decrease persistent
      postoperative pain (PPP) in surgeries with high incidence of it (Pain). Patients will be
      randomly divided in two branches; one of them will take 600 mg of Gabapentin twice a day and
      the other group will take Placebo (twice a day also).

      Both groups of patients will have to take one pill the day before the surgery (300 mg) and
      other pill on the surgery day (300mg). After that, the patients will have to continue this
      treatment during 30 days (two doses per day of Gabapentin or placebo).

      After the surgery and after taking the second pill, it will be evaluated:

      postoperative sharp pain, sickness, vomiting, sedation and adverse effects.

      Patients will be evaluated in the pain treatment office (consulting room) the following
      times:

        1. 30 days after the surgery. (taking drugs suspended)

        2. 3 month after the surgery.

        3. 6 months after the surgery.

        4. 12 months after the surgery

      This monitoring treatment will be done in order to evaluate the presence or absence of
      persistent postoperative pain (PPP).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of pain after using gabapentin.</measure>
    <time_frame>Two years</time_frame>
    <description>It will be used a 10cm ruler which will allows the patients indicates how much pain they are feeling at the moment, where 0 is no pain at all and 10 is the maximum imaginable pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg of Gabapentin per day (two doses), orally during 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300mg of Placebo per day (two doses), orally during 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>gabapentin 300 mg per day, orally during 30 days</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 300 mg per day, orally during 30 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that require persistent painfully surgeries such as breast surgeries
             (mastectomies and breast implants), herniorrhaphies (not laparoscopical) unilateral or
             bilateral, amputations of upper and lower limbs and chest surgeries (thoracotomy,
             thoracoscopy , sternotomies).

          -  Patients that had already signed the informed consent.

          -  Patients aged between 21 and 75.

          -  ASA I - II _ III (Classification system that the American Society of Anesthesiologists
             (ASA) uses to estimate the anesthesiology risk that patients may suffer)

          -  BMI, not more than 35 Kg/m2.

        Exclusion Criteria:

          -  Pregnant women

          -  Patients that suffer liver and renal failure (plasma creatinine over 1.5 mg/ml or
             creatinine clearance less than 60 ml/min),heart failure or neurological dysfunction.

          -  Diabetic patients

          -  Gabapentine allergic patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco FB Bonofiglio, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sofía Konekny</name>
      <address>
        <city>Almagro</city>
        <state>Buenos Aires</state>
        <zip>C1199ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006 May 13;367(9522):1618-25. Review.</citation>
    <PMID>16698416</PMID>
  </reference>
  <reference>
    <citation>Macrae WA. Chronic post-surgical pain: 10 years on. Br J Anaesth. 2008 Jul;101(1):77-86. doi: 10.1093/bja/aen099. Epub 2008 Apr 22. Review.</citation>
    <PMID>18434337</PMID>
  </reference>
  <reference>
    <citation>Werner MU, Kongsgaard UE. I. Defining persistent post-surgical pain: is an update required? Br J Anaesth. 2014 Jul;113(1):1-4. doi: 10.1093/bja/aeu012. Epub 2014 Feb 18.</citation>
    <PMID>24554546</PMID>
  </reference>
  <reference>
    <citation>Borsook D, Kussman BD, George E, Becerra LR, Burke DW. Surgically induced neuropathic pain: understanding the perioperative process. Ann Surg. 2013 Mar;257(3):403-12. doi: 10.1097/SLA.0b013e3182701a7b. Review.</citation>
    <PMID>23059501</PMID>
  </reference>
  <reference>
    <citation>Crombie IK, Davies HT, Macrae WA. Cut and thrust: antecedent surgery and trauma among patients attending a chronic pain clinic. Pain. 1998 May;76(1-2):167-71.</citation>
    <PMID>9696470</PMID>
  </reference>
  <reference>
    <citation>Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009 Nov 11;302(18):1985-92. doi: 10.1001/jama.2009.1568. Erratum in: JAMA. 2012 Nov 21;308(19):1973.</citation>
    <PMID>19903919</PMID>
  </reference>
  <reference>
    <citation>Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006 Aug 1;175(3):265-75. Review.</citation>
    <PMID>16880448</PMID>
  </reference>
  <reference>
    <citation>Matthews EA, Dickenson AH. Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain. 2001 May;92(1-2):235-46.</citation>
    <PMID>11323145</PMID>
  </reference>
  <reference>
    <citation>Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002 Nov-Dec;18(6):350-4. Review.</citation>
    <PMID>12441828</PMID>
  </reference>
  <reference>
    <citation>Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005 Mar;114(1-2):29-36. Epub 2005 Jan 26.</citation>
    <PMID>15733628</PMID>
  </reference>
  <reference>
    <citation>Backonja MM, Galer BS. Pain assessment and evaluation of patients who have neuropathic pain. Neurol Clin. 1998 Nov;16(4):775-90. Review.</citation>
    <PMID>9767062</PMID>
  </reference>
  <reference>
    <citation>Lavand'homme P. From preemptive to preventive analgesia: time to reconsider the role of perioperative peripheral nerve blocks? Reg Anesth Pain Med. 2011 Jan-Feb;36(1):4-6. doi: 10.1097/AAP.0b013e31820305b8.</citation>
    <PMID>21455081</PMID>
  </reference>
  <reference>
    <citation>Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 1996 Mar;12(1):56-8.</citation>
    <PMID>8722736</PMID>
  </reference>
  <reference>
    <citation>Dauri M, Faria S, Gatti A, Celidonio L, Carpenedo R, Sabato AF. Gabapentin and pregabalin for the acute post-operative pain management. A systematic-narrative review of the recent clinical evidences. Curr Drug Targets. 2009 Aug;10(8):716-33. Review.</citation>
    <PMID>19702520</PMID>
  </reference>
  <reference>
    <citation>Miller A, Price G. Gabapentin toxicity in renal failure: the importance of dose adjustment. Pain Med. 2009 Jan;10(1):190-2. doi: 10.1111/j.1526-4637.2008.00492.x. Epub 2008 Aug 18.</citation>
    <PMID>18721173</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>francisco bonofiglio</investigator_full_name>
    <investigator_title>Anesthesiology Doctor</investigator_title>
  </responsible_party>
  <keyword>Gabapentin</keyword>
  <keyword>prevention</keyword>
  <keyword>incidence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

